查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
全球 IVD（体外诊断）肿瘤诊断的增长机会
市场调查报告书
商品编码
1322964

全球 IVD（体外诊断）肿瘤诊断的增长机会

Global Oncology Diagnostics in IVD Growth Opportunities
出版日期: | 出版商: Frost & Sullivan | 英文 145 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

利用数据驱动的解决方案、共同开发机会和分析创新，使客户能够提高产品性能、成本效益和决策能力

由于癌症罹患率上升、诊断测试技术发展、筛查测试增加以及政府支持措施等因素，全球IVD（体外诊断）肿瘤诊断市场预计将显着增长。由于市场竞争日益激烈，各大公司都在研发方面投入巨资，以开发新的诊断测试。

个性化医疗是一个快速发展的行业，旨在根据每个患者的需求定制癌症治疗。这一改进得益于新诊断技术的发展，该技术可以识别驱动癌症进展的遗传异常。癌症诊断主要依赖于基因组分析，它能够检测癌症相关基因的精确突变和突变。通过分析遗传数据，医疗专业人员可以个性化治疗策略，从而改善癌症患者的治疗结果和预测预后。

目录

战略问题

  • 为什么成长如此困难？
  • The Strategic Imperative 8 (TM)
  • IVD肿瘤诊断行业三大战略问题的影响
  • 增长管道引擎 (TM)：增长机会加速

增长机会分析

  • 调查范围
  • 按测试类型细分
  • 按肿瘤类型细分
  • 按用途细分

IVD 肿瘤诊断：概述

  • 病人护理的连续性
  • 肿瘤诊断剂在精准医疗中的作用
  • 诊断在不断​​发展的精准医疗生态系统中的作用至关重要
  • 促进癌症检测的趋势

IVD 肿瘤诊断：市场动态

  • 成长指数
  • 增长促进因素
  • 生长抑製剂
  • 肿瘤诊断的主要机会及其对业务动态的影响

IIVD 肿瘤诊断：市场规模和预测

  • 肿瘤罹患率
  • 按性别分類的全球年龄标准化罹患率- 十大癌症
  • 预测假设
  • 收入预测
  • 收入预测分析
  • 按地区分類的收入预测
  • 按地区分類的收入预测分析
  • HRSA（美国）对癌症筛查推广计划的投资
  • 按测试类型分類的收入预测
  • 按检查类型分類的收入预测分析
  • 按癌症类型分類的收入预测
  • 按癌症类型分類的收入预测分析
  • 各地区癌症诊断检测报销情况汇总
  • 按用途分類的收入预测
  • 按用途的收入预测分析

竞争分析

  • 竞争环境
  • 主要竞争
  • 按级别分類的销售份额
  • 值得关注的公司：QIAGEN
  • 值得关注的公司：罗氏诊断
  • 值得关注的公司：Guardant Health
  • 值得关注的公司：Myriad Genetics
  • 值得关注的公司：Genomic Health
  • 值得关注的公司：PerkinElmer
  • 值得关注的公司：Invitae Corporation
  • 值得关注的公司：雅培实验室
  • 值得关注的公司：Illumina
  • 值得关注的公司：Natera
  • 全球肿瘤诊断市场：值得关注的活动
  • 按用途的竞争映射
  • 肿瘤诊断市场进入者：竞争基准
  • 全球肿瘤诊断公司：战略挑战

伴随诊断

  • 伴随诊断：概述
  • CDx：市场趋势
  • CDx：全球赎回概述
  • CDx：救赎挑战
  • CDx： FDA 批准作为癌症药物/生物标誌物
  • CDx：公司目标
  • 伴随诊断合作伙伴
  • FDA 批准/批准的伴随诊断 IVD 设备列表

液体活检

  • 液体活检：领先生物标誌物分析一步
  • 液体活检改善筛查和分诊途径的潜力
  • miRNA 作为癌症生物标誌物
  • 行业内液体活检公司
  • 液体活检的监管现状
  • FDA批准的液体活检测试
  • 液体活检技术及最新趋势
  • 推进液体活检引入多组学以获得全面洞察
  • 液体活检市场机会
  • 液体活检的商业化

充满增长机会的宇宙

  • 增长机会概览
  • 增长机会1：肿瘤筛查的增长趋势
  • 增长机会2：先进的综合诊断实验室
  • 增长机会 3：扩大液体活检测试的采用
  • 增长机会四：AI智能诊断
  • 增长机会 5：在亚太地区开发伴随诊断机会
  • 增长机会6：探索肺癌诊断和筛查机会

下一步

  • 下一步
  • 现在为何选择 Frost & Sullivan？
  • 附件清单
  • 免责声明
简介目录
Product Code: MGF8-55

By Leveraging Data-driven Solutions, Co-development Opportunities, and Assay Innovation, Clients Can Experience Enhanced Product Performance, Cost-effectiveness, and Improved Decision-making Capabilities

The global oncology diagnostics in IVD market is expected to witness significant growth, driven by an increase in cancer incidence, technological developments in diagnostic tests, the growing number of screening tests, and supportive government initiatives. Owing to the intense competition in the market, the most prominent companies are investing heavily in research and development to create new diagnostic tests.

Personalized medicine, a fast-growing industry, seeks to tailor cancer treatment to the individual needs of each patient. This improvement is aided by the development of new diagnostic technologies capable of identifying genetic abnormalities that cause cancer progression. Oncology diagnostics mainly relies on genomic profiling, which allows the detection of precise mutations and variations in cancer-related genes. Healthcare professionals can personalize treatment strategies by analyzing genetic data, resulting in improved treatment outcomes and the capacity to predict cancer patient prognosis.

Table of Contents

Strategic Imperatives

  • Why is it Increasingly Difficult to Grow?
  • The Strategic Imperative 8™
  • The Impact of the Top 3 Strategic Imperatives on the Global Oncology Diagnostics in IVD Industry
  • Growth Opportunities Fuel the Growth Pipeline Engine™

Growth Opportunity Analysis

  • Scope of the Study
  • Segmentation by Test Type
  • Segmentation by Cancer Type
  • Segmentation by Application

Oncology Diagnostics in IVD: An Overview

  • Patient Care Continuum
  • Role of Oncology Diagnostics in Precision Medicine
  • The Role of Diagnostics is Crucial in the Evolving Precision Medicine Ecosystem
  • Trends Driving Cancer Testing

Oncology Diagnostics in IVD: Market Dynamics

  • Growth Metrics
  • Growth Drivers
  • Growth Restraints
  • Key Oncology Diagnostics Opportunities and the Impact on Business Dynamics

Oncology Diagnostics in IVD: Market Size and Forecast

  • Oncology Incidence Rate
  • Age-standardized Global Incidence Rates Per Sex-Top 10 Cancers
  • Forecast Assumptions
  • Revenue Forecast
  • Revenue Forecast Analysis
  • Revenue Forecast by Region
  • Revenue Forecast Analysis by Region
  • HRSA's Investment in the Accelerating Cancer Screening Program (the United States)
  • Revenue Forecast by Test Type
  • Revenue Forecast Analysis by Test Type
  • Revenue Forecast by Cancer Type
  • Revenue Forecast Analysis by Cancer Type
  • Overview of Oncology Diagnostic Test Reimbursement by Region
  • Revenue Forecast by Application
  • Revenue Forecast Analysis by Application

Competitive Analysis

  • Competitive Environment
  • Key Competitors
  • Revenue Share by Tier
  • Companies to Watch-QIAGEN
  • Companies to Watch-Roche Diagnostics
  • Companies to Watch-Guardant Health
  • Companies to Watch-Myriad Genetics
  • Companies to Watch-Genomic Health
  • Companies to Watch-PerkinElmer
  • Companies to Watch-Invitae Corporation
  • Companies to Watch-Abbott Laboratories
  • Companies to Watch-Illumina
  • Companies to Watch-Natera
  • Global Oncology Diagnostics Market: Notable Activities
  • Competitive Mapping by Application
  • Oncology Diagnostic Participants: Competitive Benchmarking
  • Global Oncology Diagnostics Companies: Strategic Imperatives

Companion Diagnostics

  • CDx Overview
  • CDx Market Trends
  • CDx Global Reimbursement Overview
  • CDx Reimbursement Challenges
  • CDx FDA Approvals for Oncology Drugs and Biomarkers
  • CDx Targets by Company
  • Companion Diagnostic Partnerships
  • List of FDA-cleared/approved Companion Diagnostic IVD Devices

Liquid Biopsy

  • Liquid Biopsy: A Step Ahead in Biomarker Analysis
  • Potential of Liquid Biopsies to Improve Screening and Triage Pathways
  • miRNAs as Potential Cancer Biomarkers
  • Liquid Biopsy Companies in the Industry
  • Liquid Biopsy Regulatory Landscape
  • FDA-approved Liquid Biopsy Tests
  • Liquid Biopsy Technology and Recent Developments
  • Advancing Liquid Biopsies: Embracing Multiomics for Comprehensive Insights
  • Liquid Biopsy Market Opportunities
  • Liquid Biopsy Commercialization

Growth Opportunity Universe

  • Growth Opportunity Summary
  • Growth Opportunity 1: Growing Trend of Oncology Screening
  • Growth Opportunity 2: Advanced, Integrated Diagnostics Labs
  • Growth Opportunity 3: Increased Adoption of Liquid Biopsy Testing
  • Growth Opportunity 4: Smart Diagnostics with AI
  • Growth Opportunity 5: Unlocking CDx Opportunities in APAC
  • Growth Opportunity 6: Unleashing Opportunities in Lung Cancer Diagnostics and Screening

Next Steps

  • Your Next Steps
  • Why Frost, Why Now?
  • List of Exhibits
  • Legal Disclaimer